Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib Master Protocol Continuation Study
2024-511128-15-00Phase 4Authorised
- Sponsor
- Pfizer
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, open-label, single-arm trial of crizotinib in Neoplasm, sponsored by Pfizer. Primary endpoints: AEs leading to permanent discontinuation of crizotinib and All SAEs. Planned start May 2024; status: authorised.
02
Drugs
crizotinib
03
Conditions
Neoplasm
Beyond the preview
Go deeper on 2024-511128-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511128-15-00.